June 13, 2024
The following product safety information are essential to ensure the safe and effective use of Ranimizumab (Lucentis).
Ranimizumab (Lucentis) Product Safety Information - Diabetic Macular Edema (DME)
Ranimizumab (Lucentis) Product Safety Information - Neovascular (Wet) Age-Related Macular Degeneration (wAMD)
Ranimizumab (Lucentis) Product Safety Information - Retinal Vein Occlusion (RVO)
Ranimizumab (Lucentis) Product Safety Information - Proliferative Diabetic Retinopathy (PDR)
Ranimizumab (Lucentis) Product Safety Information - Choroidal Neovascularization (CNV)
PH2404236872